Neuromidine® (Neuromidin®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceIpidacrinIpidacrin
Similar drugsTo uncover
  • Axamon®
    solution w / m PC 
    PIK-PHARMA, LLC     Russia
  • Axamon®
    pills inwards 
    PIK-PHARMA, LLC     Russia
  • Ipigrix®
    solution w / m PC 
    GRINDEX, JSC     Latvia
  • Ipigrix®
    pills inwards 
    GRINDEX, JSC     Latvia
  • Neuromidine®
    pills inwards 
    Olainfarm, AO     Latvia
  • Neuromidine®
    solution w / m PC 
    Olainfarm, AO     Latvia
    • Dosage form: & nbsppills
    Composition:

    1 tablet contains:

    active substance: ipidakrine hydrochloride monohydrate (in terms of ipidacrine hydrochloride) 20 mg;

    Excipients: lactose monohydrate 65.0 mg, potato starch 14.0 mg, calcium stearate 1.0 mg.

    Description:Round, flat-cylindrical, with a bevel of white tablets.
    Pharmacotherapeutic group:Cholinesterase inhibitor
    ATX: & nbsp

    N.07.A.A   Anticholinesterase drugs

    Pharmacodynamics:

    Neuromidine® - has a direct stimulating effect on impulse conduction on nerve fibers, interneuronal and neuromuscular synapses of the peripheral and central nervous system.

    pharmachologic effect Neuromidine® based on a combination of two mechanisms of action:

    - blockade of the potassium channels of the membrane of neurons and muscle cells;

    - reversible inhibition of cholinesterase in synapses.

    Neuromidine® strengthens the action on smooth muscles not only acetylcholine, but also adrenaline, serotonin, histamine and oxytocin.

    Neuromidine® has the following pharmacological effects:

    - improves and stimulates impulse in the nervous system and neuromuscular transmission;

    - strengthens the contractility of smooth muscle organs under the influence of agonists acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride;

    - improves memory, inhibits the progressive course of dementia.

    At preclinical examination Neuromidine® had no teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic effects, did not affect the endocrine system.

    Pharmacokinetics:

    After ingestion, the drug is rapidly absorbed from the gastrointestinal tract. The maximum concentration in the blood plasma is reached after one hour. 40-50% of the active substance binds to blood plasma proteins. Neuromidine® quickly enters the tissue, the half-distribution period is 40 minutes. Metabolised in the liver. Excretion is carried out through the kidneys, as well as extrarenally (through the gastrointestinal tract). Excretion of the drug Neuromidine® kidneys occurs mainly through tubular secretion, and only 1/3 of the dose is released by glomerular filtration.

    Indications:

    Diseases of the peripheral nervous system: mono- and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of various etiologies.

    Diseases of the central nervous system: bulbar paralysis and paresis; the recovery period of organic lesions of the central nervous system, accompanied by motor and / or cognitive impairment.

    Treatment and prevention of intestinal atony.

    Contraindications:

    Hypersensitivity to any component of the drug, epilepsy, extrapyramidal diseases with hyperkinesis, angina and bradycardia, asthma, mechanical ileus or urinary tract, vestibular disorders, gastric ulcer or duodenal ulcer in the acute stage, pregnancy (drug increases tone of the uterus) and lactation period.

    Children under 18 years old (there are no systematized data on the application).

    Carefully:

    With peptic ulcer of stomach and duodenum, thyrotoxicosis,diseases of the cardiovascular system, as well as to patients with obstructive diseases of the respiratory system in the history or in acute respiratory diseases; with lactase deficiency, lactose intolerance, lactose / isomaltose malabsorption syndrome, since the formulation contains lactose.

    Dosing and Administration:

    Inside.

    Doses and duration of treatment are determined individually, depending on the severity of the disease.

    Diseases of the peripheral nervous system: mono- and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of different etiology - 10-20 mg (0.5-1 tablet) 1-3 times a day. The course of treatment is from one to two months. If necessary, the course of treatment can be repeated several times with a break between courses in 1-2 months.

    To prevent myasthenic crises, with severe disorders of neuromuscular conduction for a short time parenterally inject 1-2 ml (15-30 mg) Neuromidine® 1.5% solution for injection, then continue treatment with tablets Neuromidine®, the dose can be increased to 20-40 mg (1-2 tablets) 5 times a day.

    Diseases of the central nervous system: bulbar paralysis and paresis, the recovery period of organic lesions of the central nervous system (traumatic, vascular and other genesis), accompanied by motor and / or cognitive impairment - 10-20 mg (0.5-1 tablet) 2-3 times a day. The course of treatment is from 2 to 6 months. If necessary, repeat the treatment.

    Treatment and prevention of intestinal atony: 20 mg (one tablet) 2-3 times a day for 1-2 weeks.

    If the next dose was not taken on time, then it is not taken in addition. The maximum daily dose is 200 mg.

    Side effects:

    Caused by excitation of m-holinoretseptorov: drooling, increased sweating, palpitations, nausea; diarrhea, jaundice, bradycardia, epigastric pain, increased secretion of bronchial secretions, bronchospasm, convulsions. Salivation and bradycardia can be reduced by m-holinoblokatorami (atropine and etc.).

    Increase in the tone of the uterus, skin allergic reactions.

    Rarely, after applying higher doses, dizziness, headache, chest pain, vomiting, general weakness, drowsiness, skin reactions (itching, rash) were observed. In these cases, reduce the dose or briefly (for 1-2 days) interrupt the reception of the drug.

    These side effects are observed in less than 10% of patients.

    Overdose:

    Symptoms: decreased appetite, bronchospasm, lacrimation, sweating, pupillary constriction, nystagmus, increasing motility of the gastrointestinal tract, spontaneous defecation and urination, vomiting, jaundice, bradycardia, impaired intracardiac conduction, arrhythmias, blood pressure, anxiety, worry, agitation, a feeling fear, ataxia, convulsions, coma, speech disorders, drowsiness and general weakness.

    Treatment: apply symptomatic therapy, use m-holinoblokatory: atropine, cyclodol, metacin, and others.

    Interaction:

    Neuromidine® enhances sedation in combination with drugs that depress the central nervous system.

    Effects and side effects are enhanced when combined with other cholinesterase inhibitors and m-cholinomimetic agents.

    In patients with myasthenia gravis, the risk of developing a cholinergic crisis increases, if you apply Neuromidine® simultaneously with other cholinergic agents.

    The risk of bradycardia increases if β-blockers were used before the drug was started Neuromidine.

    Neuromidine® can be used in combination with nootropic drugs.

    Relieves the depressing effect on neuromuscular transmission and conduction of excitation along the peripheral nerves of local anesthetics, aminoglycosides, potassium chloride.

    Special instructions:

    There are no systematized data on the use of the drug Neuromidine® in children.

    For the duration of treatment, alcohol should be excluded. Alcohol increases the side effects of the drug.

    Effect on the ability to drive transp. cf. and fur:

    During treatment should refrain from driving, as well as practicing potentially dangerous activities that require increased concentration and speed of psychomotor reactions.

    Form release / dosage:Tablets, 20 mg.
    Packaging:

    10 tablets per contour cell packaging made of polyvinylchloride film and aluminum foil.

    For 5 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

    Storage conditions:

    In a dry, the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years.

    Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:П N014238 / 01
    Date of registration:16.03.2011
    Expiration Date:Unlimited
    The owner of the registration certificate:Olainfarm, AOOlainfarm, AO Latvia
    Manufacturer: & nbsp
    Representation: & nbspOLAINFARM JSC OLAINFARM JSC Latvia
    Information update date: & nbsp27.06.2018
    Illustrated instructions
      Instructions
      Up